Upsher-Smith, NASPA honor 45 pharmacists
Upsher-Smith Labs and the National Alliance of State Pharmacy Associations have announced the recipients of the 2017 NASPA Excellence in Innovation award.
The award, sponsored by the Maple Grove, Minn.-based manufacturer and coordinated by NASPA, recognized 45 pharmacists for their contributions to the pharmacy profession. The pharmacists received the award from their state pharmacy associations over the course of 2017.
“Upsher-Smith is proud to be a continued sponsor of NASPA’s Excellence in Innovation Award,” Upsher-Smith president and CEO Rusty Field said. “We are honored to give recognition to these awardees that have demonstrated innovation in the pharmacy profession and advanced patient care. Upsher-Smith shares these values and understands the critical role pharmacy plays in improving the health and lives of patients.”
The award is meant to recognize pharmacists who have shown significant innovation in their practice, method or service that results in improved patient care or advancing the profession of pharmacy.
“We appreciate Upsher-Smith for supporting the Excellence in Innovation Award,” NASPA executive vice president and CEO Rebecca Snead said. “The pharmacists honored have demonstrated exemplary professional achievements and innovation. We are proud to partner with Upsher-Smith and recognize these leaders for their commitment to advancing the pharmacy profession and improving the lives of patients across America every day.”
The pharmacists recognized were:
- Alabama: Patrick Devereux;
- Alaska: Karen Thompson;
- Arizona: Alyssa M. Peckham;
- Arkansas: Jody Smotherman;
- California: Christine Givant;
- Colorado: Paul B. Shaw;
- Connecticut: Ellen Jones;
- Delaware: Stephanie Pro;
- Florida: Damien D. Simmons;
- Georgia: Jennifer Shannon;
- Illinois: Starlin Haydon-Greatting;
- Indiana: Carrie Morton;
- Iowa: Jordan Schultz;
- Kansas: Molly Aldrich;
- Kentucky: Melanie Dicks, Holly Divine and Tera McIntosh;
- Louisiana: Jennifer Boudreaux;
- Maine: Courtney Doherty Oland;
- Maryland: Neil Leikach and Dixie Leikach;
- Massachusetts: Allison E. Burns;
- Michigan: Andrew J. Reeves;
- Minnesota: Anjoli Punjabi;
- Mississippi: Amanda Wilburn;
- Missouri: Stuart D. Federman;
- Montana: Michael F. Bertagnolli;
- New Hampshire: Eric R. Lessard;
- New Jersey: Domenic DiPrimo;
- New Mexico: Brian Hunt;
- New York: Christopher Daly;
- North Carolina: Robert F. Carta;
- North Dakota: Briana D. Fluhrer;
- Ohio: Erin L. Thompson;
- Oklahoma: Travis B. Wolff;
- Pennsylvania: Melissa Somma McGivney;
- Rhode Island: Linda Rowe-Varone;
- South Carolina: Deborah D. Bowers;
- Tennessee: Philip J. Baker;
- Virginia: Tana Kaefer;
- Washington: Monica Graybeal;
- Washington; DC: Carlisha Gentles;
- West Virginia: Jason Turner;
- Wisconsin: Erica Guetzlaff; and
- Wyoming: Shawn Dalton.
Lupin intros Tamiflu generic
Lupin has launched its generic of Tamiflu (oseltamivir) capsules. The drug is indicated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older who’ve shown symptoms for no more than 48 hours. It also is indicated to prevent the flu in patients age 1 year and older.
Lupin’s generic will be available in 30-, 45- and 75-mg (base) dosage strengths. The product had U.S. sales of roughly $518 million for the 12 months ended December 2017, according to IQVIA data.
Gilead’s freshly approved Biktarvy faces patent hurdle
Gilead Sciences’ new HIV treatment Biktarvy has been approved by the Food and Drug Administration — but its novel component is also the subject of patent infringement litigation from GSK.
Biktarvy is a triple-therapy HIV treatment that brings together bictegravir’s unboosted integrase strand transfer inhibitor with the dual nucleoside transcriptase inhibitor backbone of emtricitabine, tenofovir alafenamide — which are the two components of Gilead’s Descovy.
“Gilead is committed to improving care and simplifying therapy for people living with HIV. We continue to invest in research in next-generation treatments, including therapies that could potentially cure HIV patients,” Gilead president and CEO John Milligan said. “We are pleased to offer Biktarvy, our latest triple-therapy treatment, which brings together the potency of an integrase inhibitor with the most-prescribed dual-NRTI backbone in a once-daily single tablet regimen.”
However, now bictegravir is at the center of GSK’s lawsuit, which was filed in the U.S. District Court for the District of Delaware, as well as in Canadian Federal Court in Toronto. GSK’s majority-owned Viiv Healthcare said it is looking to prove that Biktarvy’s use of bictegravir infringes on a patent covering its dolutegravir and other compounds that use dolutegravir’s chemical scaffold. The company said it would seek financial redress.
“Intellectual property protections are critical for the life-sciences industry, allowing companies to make a return on their investment, which in turn enables research-based companies to put new funding into research and development,” GSK said. “It is this cycle which continues to result in the development of new and much-needed treatments for people living with HIV.”